Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5%.".